Allspring Global Investments Holdings LLC Acquires 21,085 Shares of Prestige Consumer Healthcare Inc. $PBH

Allspring Global Investments Holdings LLC increased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,613,460 shares of the company’s stock after purchasing an additional 21,085 shares during the quarter. Allspring Global Investments Holdings LLC owned 3.36% of Prestige Consumer Healthcare worth $98,776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. AQR Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare by 11.9% in the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after acquiring an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after purchasing an additional 1,289 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC boosted its holdings in Prestige Consumer Healthcare by 204.0% in the first quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after purchasing an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its position in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.40% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Trading Up 1.2%

NYSE:PBH opened at $59.24 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 1.84 and a beta of 0.41. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $89.37. The business has a fifty day moving average price of $65.18 and a 200-day moving average price of $63.03.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. During the same quarter last year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group dropped their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $76.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).